Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Has Consensus Target Price of $99.07

Posted by Brian Himes on Oct 26th, 2026

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $99.07.

Several research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. UBS Group began coverage on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. They set a “buy” rating and a $109.00 target price on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. JPMorgan Chase & Co. boosted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th.

Read Our Latest Report on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $58.02 on Friday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a market cap of $8.17 billion, a PE ratio of -25.79 and a beta of 1.29. The business has a 50 day moving average of $72.62 and a 200 day moving average of $75.86. Arrowhead Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The business’s revenue was up 171.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.26) EPS. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently made changes to their positions in ARWR. Versant Capital Management Inc raised its holdings in Arrowhead Pharmaceuticals by 285.1% in the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 154 shares in the last quarter. Optiver Holding B.V. boosted its holdings in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $39,000. Finally, Allied Private Wealth LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at $43,000. 62.61% of the stock is currently owned by institutional investors.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.